8月13日A股投資避雷針︱恆信東方:因涉嫌信息披露違法違規 收到證監會立案告知書
唐人神股東大生行擬減持不超過993.44萬股;麥捷科技高管張照前、樑啓新擬減持合計不超59.91萬股;天億馬股東南京樂遂、南京優志擬合計減持不超過3.46%股份;曼卡龍控股股東擬減持不超過3%股份;四方精創控股股東及其一致行動人擬減持不超過2.25%股份;康華生物股東川發精選3號擬減持不超過3%股份;惠泰醫療副董事長、總經理成正輝擬大宗交易減持不超2%股份;雙一科技控股股東王慶華及其一致行動人擬合計減持不超0.7923%股份;恆信東方因涉嫌信息披露違法違規 收到證監會立案告知書;*ST華微無法在責令改正期限內完成資金佔用整改 股票停牌

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.